Market Intelligence, Clinical Progress, and High-Purity Reagents for Glioblastoma and Solid Tumor Fusion Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MSANTD3-TMEFF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MSANTD3-TMEFF1 Fusion Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View MSANTD3-TMEFF1 Products |
| Gene Delivery | MSANTD3-TMEFF1 Promise-ORF / Lentivirus Full-length fusion ORF for stable cell line construction. |
View MSANTD3-TMEFF1 Products |
| Benchmark Ab | Anti-TMEFF1 Recombinant Antibody Recombinant positive control for target validation. |
View TMEFF1 Products |
| Validator | MSANTD3-TMEFF1 siRNA Set For knockdown verification in oncogenic dependency assays. |
View MSANTD3-TMEFF1 Products |
| Related Target A | TMEFF1 Wild-type partner; critical for counter-screening and off-target toxicity profiling. |
View TMEFF1 Products |
| Related Target B | MSANTD3 Wild-type chromatin regulator; essential for assessing fusion-specific binding. |
View MSANTD3 Products |
| Related Target C | BMP4 TMEFF1 acts as a BMP antagonist; critical for downstream functional readout validation. |
View BMP4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Fusion-specific epitope mapping | Custom-designed MSANTD3-TMEFF1 junction peptides and proteins with sequence verification |
| Stable expression in glioblastoma models | High-titer Lentiviral vectors optimized for hard-to-transfect brain tumor cell lines |
| Lack of Controls | Recombinant wild-type TMEFF1 and MSANTD3 benchmark proteins included |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown validation |
Live MSANTD3-TMEFF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The discovery of the recurrent MSANTD3-TMEFF1 fusion transcript has opened a novel therapeutic window in neuro-oncology, particularly for pediatric and adult glioblastoma multiforme (GBM). As a driver of aberrant transcriptional programs and altered cell-surface signaling, this fusion bypasses classical receptor tyrosine kinase (RTK) pathways, rendering standard-of-care therapies ineffective.
The race for MSANTD3-TMEFF1 therapeutics is intensifying, with major players shifting focus from traditional systemic mAbs to blood-brain barrier (BBB)-penetrating small molecules, degraders (PROTACs), and targeted RNA therapeutics. As first-generation diagnostic assays reach clinical validation, the next wave of R&D is targeting the unique fusion junction and downstream BMP-antagonist pathways to selectively eliminate fusion-positive tumor cells while sparing normal brain tissue.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA / RNAi | Alnylam, Arrowhead (Academic Collaborations) | Glioblastoma (GBM), Astrocytoma | In vitro knockdown validation (Need sequence-verified siRNA & Lentivirus) |
| Small Molecule / PROTAC | Academic Consortia, Biotech Startups | Refractory Brain Tumors | Selectivity assay (Need Mutant/Fusion vs. WT MSANTD3/TMEFF1 recombinant proteins) |
| Targeted mAbs / ADCs | Innovator Biopharma | Solid Tumors expressing TMEFF1 | Internalization and binding assays (Need HEK293-expressed TMEFF1 ECD-Fc) |